
Good morning, HealthTech insiders. OpenAI is going after one of healthcare's most stubborn problems: the administrative work trapped inside disconnected software. Its new computer-use agents can navigate EHRs and insurer portals like a human, with CVS Health and Cigna already putting them to work. In testing, reviewers rated 99% of 325 EHR inbox tasks clinically safe.
And that's only one of three big developments in today's Signal. Apple has launched a 200,000-person study to understand whether consumers trust AI health advice, while Medtronic is acquiring Contego Medical for $380 million, days after a major FDA approval. Different strategies, one underlying shift: healthcare technology is moving from proving what it can do to proving it can be trusted.
In today's Signal:
OpenAI (November 16): Computer-use agents achieve 99% clinical safety ratings across 325 reviewed EHR inbox tasks, with CVS Health, Cigna, Abridge and Ambience adopting the technology.
Apple (November 15): Partners with OpenEvidence on a study of up to 200,000 Americans to evaluate trust, comprehension and use of AI-generated health information.
Medtronic (November 16): Agrees to acquire Contego Medical for $380 million plus potential payments, expanding into newly approved transcarotid stenting technology.
Plus: New HIPAA records access rules, MiniMed's first tubeless insulin pump and Noom's employer-focused wearable.
Analytics on Live Data Without Leaving Postgres
When analytics on Postgres slows down, most teams add a second database. Then come the pipelines, the sync jobs, and a copy of your data that's always a little behind.
TimescaleDB takes a different approach: extend Postgres instead of splitting away from it. Hypertables partition your data automatically as volume grows. Hypercore compression cuts storage up to 95%. Continuous aggregates keep dashboards live without re-querying everything.
CERN runs Postgres this way for sensor data from the Large Hadron Collider.
No split architecture, no pipeline lag, no new query language to learn. Same SQL, same drivers, same tools.
Start on Tiger Cloud and get $1000 in credits.
LATEST DEVELOPMENTS
ENTERPRISE AI
1. OpenAI Puts Computer-Use Agents to Work at CVS Health and Cigna, Rated Safe on 99% of Reviewed Clinical Tasks

Image credit: OpenAI
On November 16, OpenAI introduced new healthcare computer-use capabilities that allow AI agents to click, type and complete workflows across software without APIs. CVS Health, Cigna Healthcare, Abridge and Ambience are among the organizations developing or deploying the technology.
The details:
Performance: Reviewers rated 99% of 325 EHR inbox tasks clinically safe. GPT-6 Astra scored 94.3% on Stanford's HealthAdminBench, while GPT-6 Luna achieved 91.8% at a reported 8.5 cents per task. These are OpenAI-reported evaluations.
Real deployments: A CVS Health agent cleared a months-long document backlog over a weekend, while another handles workflows supporting tens of thousands of daily consults. Cigna moved from concept to deployment in under eight weeks.
Safety controls: Ambience's prior authorization agent requests clinician approval when needed. Abridge is developing inpatient agents, while OpenAI added more than 20 healthcare plugins connecting additional systems.
The Signal: Computer-use agents could finally automate the countless workflows that traditional integrations have left untouched. But lower execution costs create a new challenge: governance. As agents navigate insurer portals and clinical systems, human approval, access controls and auditable decisions will determine who scales successfully. The competitive advantage is shifting from generating answers to safely completing work.
CONSUMER HEALTH AI
2. Apple and OpenEvidence Launch a 200,000-Person Health AI Study

Apple and OpenEvidence have launched a study involving up to 200,000 U.S. participants to understand trust, comprehension and everyday use of AI-generated health information. Image credit: Apple
On November 15, Apple launched the Apple Health AI Usage Study with OpenEvidence to examine how consumers interact with AI-generated health information. The U.S. study will enroll up to 200,000 adults and evaluate trust, comprehension and health-related decisions.
The details:
The experience: Participants receive plain-language answers backed by peer-reviewed medical sources, including journals such as JAMA and The New England Journal of Medicine.
Eligibility and data: Adults aged 21 and older with an Apple Intelligence-enabled iPhone 15 Pro or later can participate. Sharing HealthKit information, including sleep, activity and health measurements, is optional.
Privacy: Apple says study data will not train AI models. The app is intended for health education and visit preparation, not diagnosis or treatment.
The Signal: Apple is studying consumer behavior before committing to a broader health AI product. That matters because medical accuracy alone does not guarantee trust or better decisions. By partnering with OpenEvidence, Apple is testing whether evidence-backed answers can bridge the gap between patients and clinicians. In consumer health AI, trust could become as valuable as the underlying model.
MEDTECH
3. Medtronic to Acquire Contego Medical for $380 Million After FDA Approval

Medtronic has agreed to acquire Contego Medical for $380 million plus potential payments, expanding its carotid intervention portfolio with the newly FDA-approved Neuroguard IEP Direct System. Image credit: Contego Medical
On November 16, Medtronic announced plans to acquire Contego Medical for $380 million plus potential payments. The agreement follows FDA approval of Contego's Neuroguard IEP Direct System, strengthening Medtronic's position in carotid artery disease treatment.
The details:
The technology: Approved November 10, Neuroguard IEP Direct combines flow reversal with an integrated 40-micron filter to capture debris during transcarotid artery revascularization (TCAR).
Clinical evidence: Contego reported zero strokes through 30 days in its PERFORMANCE III pivotal study, alongside a 0.69% major adverse event rate. These are single-arm results, not comparative evidence.
The acquisition: Medtronic has exclusively distributed Neuroguard IEP since January 2025. The deal also adds Contego's Excipio thrombectomy portfolio and is expected to close in Medtronic's fiscal third quarter.
The Signal: Medtronic's strategy is familiar: invest early, establish a distribution relationship and acquire after regulatory approval reduces uncertainty. Contego strengthens its position against Boston Scientific in carotid revascularization. But the next competitive test is clinical adoption and comparative performance, not the approval itself. Large MedTech buyers continue to favor validated assets with clearer commercial pathways.
QUICK HITS
👀 WHAT WE'RE WATCHING NEXT
AI agents and prior authorization: Whether providers publish clear approval and audit policies as agents begin navigating payer portals alongside emerging CMS API requirements.
Apple's health AI study: Early findings on consumer trust, comprehension and whether evidence-backed answers eventually reach Apple's wider Health ecosystem.
Contego's commercial rollout: Medtronic's integration strategy, comparative TCAR evidence and updates during its November 24 earnings announcement.
💰 FOLLOW THE MONEY
The deals:
Medtronic: $380M acquisition of Contego Medical, plus potential payments, securing its newly FDA-approved carotid stenting technology.
Remedy Robotics: $62M Series B led by DCVC to advance its AI-enabled endovascular robotics platform toward pivotal trials.
Knit Health: $35M Series A led by NEA to develop Med-BEAM, its healthcare prediction model.
Commure: Acquired clinical inbox automation company Elaborate for an undisclosed amount.
Credo Health: Acquired Affineon Health and relaunched as Pajama.ai, combining AI-assisted pre-visit and post-visit workflows.
The pattern: Investors are backing technology that delivers measurable operational value, while strategic buyers favor proven clinical assets. OpenAI's reported 8.5-cent administrative task benchmark adds pressure on traditional automation economics. The opportunity is increasingly in reliable deployment, integration and outcomes rather than standalone AI capabilities.
📆 UPCOMING HEALTHTECH EVENTS
HLTH USA 2026: November 15–18 · Las Vegas, Nevada
Under way, with agentic AI, payer workflows and consumer health technology taking center stage.RSNA 2026: November 29–December 3 · Chicago, Illinois
A major showcase for diagnostic imaging AI, clinical workflow tools and radiology innovation.45th Annual J.P. Morgan Healthcare Conference: January 11–14, 2027 · San Francisco, California
A key gathering for healthcare investment, partnerships, acquisitions and strategic outlooks. jpmorgan.com
🛠️ Trending HealthTech AI Tools
Luma Health plugin for ChatGPT: Introduced November 16, offering 59 actions covering scheduling, referrals, messaging, procedure preparation and payment follow-ups, integrated with existing EHR permissions.
Scale for Hospital Operations: Five new AI agents for referral management, order guidance, medical record review, safety investigations and documentation, designed for deployment within health system environments. scale.com
Elaborate, now part of Commure: Uses clinician-controlled protocols to manage patient portal messages inside the EHR. Commure reports up to 36% less inbox time and 15% fewer patient messages at participating health systems. commure.com
🛠️ Trending HealthTech AI Startups
Remedy Robotics: Raised a $62M Series B led by DCVC to advance its N1 robotic platform for on-site and remote endovascular procedures, including a planned neurovascular pivotal trial.
Pajama.ai: Relaunched after Credo Health acquired Affineon, bringing chart preparation, lab results and prescription renewal workflows into one AI assistant. The company targets approximately 40 hours of physician time saved monthly. prnewswire.com
Knit Health: Secured $35M in Series A funding led by NEA for Med-BEAM, a model predicting patient journeys and clinical events. The company claims four times better prediction performance at 250 times lower cost than leading language models. knit.health
DECISION INTELLIGENCE
Highlights: Deep Dives & Industry Reports
The Agent Behind the Portal: What OpenAI's Computer-Use Results Mean for Prior Auth, Payers and Health System IT
Inside the 99% safety results, automation economics, real deployments and the governance challenges facing healthcare agents.Study First, Ship Later: Apple, OpenEvidence and the Race to Earn Trust in Consumer Health AI
Why Apple is studying 200,000 consumers, what OpenEvidence contributes and how trust could shape the next health AI market.Buying the Filter: Medtronic, Contego and the Next Phase of Carotid Revascularization
The technology behind Neuroguard, its clinical evidence and what Medtronic's $380 million acquisition reveals about MedTech dealmaking.
Where would you let a computer-use agent act first in your organization?
That's it for today!
OpenAI is teaching agents to navigate healthcare's disconnected systems. Apple is testing whether people trust AI health information before expanding its use. And Medtronic is paying for technology that has already cleared a major regulatory hurdle.
Three different approaches, one emerging reality: in healthcare, the next competitive advantage is permission to act, backed by evidence.
Which will scale faster: AI agents in hospital back offices or health AI in patients' pockets?
How did we do today?
See you tomorrow,
Dr. Dereck Mush, MD, MBA
The HealthTech Signal is independently funded. Sponsorships help us invest in better reporting, research, and a stronger newsletter for our readers. Want to reach HealthTech founders & executives while supporting the Signal? Get in touch.
Was this email forwarded to you? Sign up here.
Until tomorrow,
The HealthTech Signal



